Abstract: Method of treating leukemia, inhibiting the growth or proliferation of leukemic cells or extending the life span of a animal having leukemia are disclosed. The methods comprise the step of treating the leukemia with an effective amount of a compound of the Formula I
or a pharmaceutically acceptable salt or prodrug form thereof, wherein:
X is hydrogen, halogen or alkyl of less than 7 carbon atoms;
n is a positive integer of less than 4;
Y is hydrogen, chlorine, nitro, methyl or ethyl;
R is hydrogen or an alkyl group of from 1 to 8 carbon atoms, alkylcarbamyl;
R2 is 4-thiazolyl or NHCOOR1; and
R1 is an aliphatic hydrocarbon of less than 7 carbon atoms.
A chemotherapeutic agent and/or potentiator can be used in conjunction with the compound of the Formula I.
Abstract: Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amounts of platinum-containing chemotherapeutic agents such as cisplatin are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.
Type:
Grant
Filed:
April 8, 1998
Date of Patent:
July 24, 2001
Assignee:
Southern Illinois University School of Medicine
Abstract: Derivatives of Quinazoline are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
Abstract: Compounds selected from the group of compounds represented by Formula I:
as an individual isomer or as a racemic or non-racemic mixture of isomers, and their pharmaceutically acceptable salts and N-oxides thereof; are sodium channel blockers, and thus exhibit useful pharmacological properties, including utility for the treatment of neuropathic pain conditions.
Type:
Grant
Filed:
April 20, 2000
Date of Patent:
July 17, 2001
Assignee:
Syntex (U.S.A.) LLC
Inventors:
David Garrett Loughhead, Xiao-Fa Lin, Robert James Weikert, Lee Allen Flippin
Abstract: This invention provides combination therapy methods, pharmaceutical combinations and compositions for inducing tumor cell regression in cancer patients, particularly metastatic breast cancer patients. The combination methods, combinations and compositions employ both edatrexate and a taxane which are administered simultaneously or sequentially. The combination therapy described here permits the administration of unusually high doses of edatrexate.
Type:
Grant
Filed:
February 1, 1996
Date of Patent:
July 17, 2001
Assignee:
Sloan-Kettering Institute of Cancer Research
Inventors:
David William Fennelly, Francis Michael Sirotnak
Abstract: A pharmaceutical composition for reducing the rate at which skin ages or for treating cancer, acne or rosacea. The composition comprises a pharmaceutically acceptable excipient in combination with 26, 27-hexafluoro-1,25-dihydroxy vitamin D3. The composition is preferably administered topically at a concentration of about 0.0001% weight to about 0.01% weight.
Abstract: Activation of the Ki-ras proto-oncogene is common in colon carcinogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit carcinogen-induced colon carcinogenesis, decrease the frequency of Ki-ras mutations in the azoxymethane-treated rat model, and induce apoptosis in a variety of cell types. Sulindac, as well as other non-steroidal anti-inflammatory agents, are provided in combination with DFMO the prevention and/or treatment of cancers characterized by the expression of an activated Ki-ras. Provided with the present invention are pharmaceutically acceptable compositions that include a non-steroidal anti-inflammatory agent, sulindac, together with an effective amount of difluoromethylornithine.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
July 10, 2001
Assignees:
The Regents of the University of California, Arizonia Board of Regents Behalf of the University of
Arizonia
Inventors:
Eugene W Gerner, Frank L. Meyskens, Jr.
Abstract: Herein is disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetylglutamine and phenylacetylisoglutamine in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. In a further embodiment, herein is also disclosed a method of treating neoplastic disease, including cancer, comprising administering a pharmaceutical composition, the pharmaceutical composition comprising a highly concentrated aqueous solution of phenylacetate and (phenylacetylglutamine or phenylacetylisoglutamine) in a 4:1 ratio, at an infusion rate of from 100 mL/hr to 400 mL/hr. Herein are also disclosed the pharmaceutical compositions used in the above methods.
Abstract: The present invention relates generally to the fields of chemotherapeutic treatments. More particularly, it concerns the use of ibuprofen, a non-steroid anti-inflammatory drug, in the treatments of disease. More particularly, it has been discovered that the R-enantiomer of ibuprofen, previously thought to be inactive, may be used as an antineoplastic agent and also in the prophylactic and therapeutic treatment of Alzheimer's and Alzheimer's related diseases.
Type:
Grant
Filed:
June 20, 1997
Date of Patent:
July 3, 2001
Assignee:
Advanced Research and Technology Institute
Abstract: Methods are disclosed for treating cancer in a patient in need of such treating comprising administering temozolomide in an amount effective to achieve a clinical response wherein the temozolomide is administered in a microcrystalline suspension.
Abstract: This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains N-chlorophenylcarbamates and N-chlorophenylthiocarbamates along with a chemotherapeutic agent and optionally a potentiator. A composition for treating viral infections in animals or humans comprising a safe and effective amount of N-chlorophenylcarbamates and the N-chlorophenylthiocarbamates and a potentiator is also disclosed.
Abstract: Pharmaceutically acceptable compositions suitable for releasing magnesium ions to an organism, such as organic or inorganic magnesium salts or complexes thereof, are used to prevent and to treat neoplastic and autoimmune diseases, whose origin can be attributed to magnesium depletion. For the new therapeutic indications the magnesium based product, preferably magnesium pyrophosphate, is usually administered orally or parenterally, preferably in association with vitamin B6.
Abstract: Use of compounds of the formula I
for preparing a medicated for protecting DNA in the initial phase and/or the prompting phase of carcinogenesis and for preventing oxidating stress in patients with diseases related to free radicals are described.
Type:
Grant
Filed:
June 24, 1997
Date of Patent:
June 19, 2001
Inventors:
Jan Bergman, Lennart Möller, Hans Vallberg
Abstract: Derivatives of Phenyl Pyrimidinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.
Abstract: The present invention provides a method of inhibiting tumor progression in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Also provided is a method of inhibiting metastasis in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a phospholipase C inhibitor. Further provided are pharmaceutical compositions, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis and a pharmaceutically acceptable carrier and a pharmaceutical composition, comprising a phospholipase C inhibitor of tumor invasiveness and metastasis, a antineoplastic agent and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
March 25, 1997
Date of Patent:
May 22, 2001
Assignee:
UAB Research Foundation
Inventors:
Philip Chen, Timothy Turner, Alan Wells
Abstract: This invention provides a method of identifying and reversing multidrug resistance in a multidrug resistance tumor comprising administering a multidrug resistance reversing amount of any of the compounds as defined herein.
Type:
Grant
Filed:
February 26, 1997
Date of Patent:
May 22, 2001
Assignee:
Eli Lilly and Company
Inventors:
Gabriele Jedlitschky, Inka Leier, Dietrich Keppler
Abstract: A new use of the botanical substance Capsaicin entails application of Capsaicin to pre-malignant basal and squamous cell lesions of the epithelium. Advantageous treatment, including atrophication and de-coloration of such lesions is accomplished. The substance, which is applied topically, is employed in a potency, or concentration, of about 0.010% to 0.200% (w/w). Capsaicin in the same potency can also be employed in a base of aloe vera.
Abstract: The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:
Type:
Grant
Filed:
October 12, 1999
Date of Patent:
May 15, 2001
Assignee:
American Home Products Corporation
Inventors:
Chris P. Miller, Michael D. Collini, Bach D. Tran, Arthur A. Santilli
Abstract: Combinations of substituted indenyl acetic acids and pyrimido-pyrimidine derivatives are useful in the treatment of colonic polyps and inhibiting the growth of neoplastic cells.
Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″-(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
Type:
Grant
Filed:
April 30, 1997
Date of Patent:
May 15, 2001
Assignee:
Eli Lilly and Company
Inventors:
Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways